TNTomoo Nakagawa

Tomoo Nakagawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tomoo Nakagawa has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

    by Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi

    An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease. Patients were prospectively enrolled between November 2014 and March 2017, after the launch of CT-P13 in Japan, and case report forms of patients followed for at least 4 months were analyzed as of July 2018. Of 523 patients in the analysis set, 372 remained on CT-P13 therapy, while 54 (20.2%) of 267 patients with Crohn's disease, and 97 (37.9%) of 256 patients with ulcerative colitis were withdrawn during follow-up. A total of 144 adverse drug reactions (ADRs) were reported in 106 patients (20.3%). Infusion reaction was the most frequent ADR observed in 49 patients (9.4%). Efficacy parameters decreased immediately after the start of treatment in naïve patients to anti-tumor necrosis factor-α antibody. In the patients switched from originator infliximab for nonmedical reasons, the decreased parameters due to proceeded treatment with the originator were maintained in low ranges, and the treatment continuation rate was high with low ADR incidence. In contrast, in patients switched for medical reasons such as adverse event or loss of response, the incidence of ADRs was high. However, the efficacy parameters were improved, and the treatment continuation rate was not significantly different from that of the naïve patient group. In this interim analysis, CT-P13 was comparable to the originator infliximab with respect to ADRs and efficacy, and is therefore considered to be a cost-efficient interchangeable biosimilar for Japanese patients with inflammatory bowel disease.


  • Open Access

    Novel three-dimensional imaging system may facilitate gastric endoscopic submucosal dissection procedure: an ex vivo animal study

    by Naoki Akizue, Tomoaki Matsumura, Daisuke Maruoka, Kentaro Ishikawa, Dao Viet Hang, Kenichiro Okimoto, Keiko Saito, Tomoo Nakagawa, Makoto Arai, Naoya Kato

    Background and study aims Endoscopic submucosal dissection (ESD) requires advanced skills to perform safely without complications. The current study evaluated the usefulness of a novel three-dimensional (3D) imaging system in ESD using porcine stomachs. Methods Four endoscopists (two trainees and two experts) performed eight ESD procedures using both 3D and 2D images. The usefulness of 3D image versus 2D image was evaluated by visibility and procedure time. In addition, occurrence of eyestrain and dizziness in 3D image was assessed. Results En bloc resection was successfully achieved, without perforation, in all cases. The evaluation score in the 3D image group was better than that in the 2D image group, particularly depth perception was statistically significantly good. No significant difference was found in the working speed between the 2D and 3D image groups. Two examiners experienced eyestrain and dizziness while using the 3D image. Conclusions All the ESD procedures were performed safely. Depth perception using the 3D image was better than with the 2D image. A novel 3D image system may facilitate ESD.


  • The Effect of Ineffective Esophageal Motility on Gastroesophageal Reflux Disease

    by Shingo Kasamatsu, Tomoaki Matsumura, Yuki Ohta, Shinsaku Hamanaka, Hideaki Ishigami, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Daisuke Maruoka, Tomoo Nakagawa, et al.

    Background/Aims: Ineffective esophageal motility (IEM) is the most common gastrointestinal motility disorder. Studies have reported that IEM is related to gastroesophageal reflux disease (GERD). However, the relationship between IEM and GERD remains uncertain. This study aims to clarify this relationship retrospectively. Methods: We analyzed 195 subjects who underwent high-resolution manometry between January 2011 and September 2016. Of these subjects, 72 had normal esophageal motility (NEM) and 26 had IEM. We investigated differences in the clinical characteristics, severity and duration of GERD symptoms, and comorbid extra-esophageal symptoms of the subjects. Comorbid extra-esophageal symptoms were assessed with the Gastrointestinal Symptom Rating Scale questionnaire. Investigation-defined GERD was diagnosed when erosive esophagitis or abnormal multichannel intraluminal impedance was present. Results: We found no significant difference in the prevalence of IEM between patients with and without GERD (37.5 and 21.1%, respectively; p = 0.174). There were no differences in age, gender, body mass index, presence of hiatal hernia, or duration of GERD between the groups. Compared to patients with NEM, those with IEM were significantly less likely to have comorbid extra-esophageal symptoms (p < 0.05). Conclusion: There is no association between IEM and GERD.


  • Heparin‐bridging therapy is associated with a high risk of post‐polypectomy bleeding regardless of polyp size

    by Hideaki Ishigami, Makoto Arai, Tomoaki Matsumura, Daisuke Maruoka, Shoko Minemura, Kenichiro Okimoto, Shingo Kasamatsu, Keiko Saito, Tomoo Nakagawa, Tatsuro Katsuno, et al.

    Background and Aim: Evidence regarding safety and efficacy of heparin‐bridging therapy for colonoscopic polypectomy remains scarce. The aim of the present study was to evaluate the risk of post‐polypectomy bleeding (PPB) in patients receiving heparin‐bridging therapy.Methods: We retrospectively reviewed the database of patients who underwent colonoscopic polypectomy with prophylactic clip closure between January 2007 and December 2014 at our institution. We evaluated patients receiving heparin‐bridging therapy (HB group) compared with those who did not receive antithrombotic therapy (No‐HB group).Results: A total of 1421 polypectomies were carried out on 773 patients; 45 patients were in the HB group and 728 patients were in the No‐HB group. The incidence of PPB per patient was significantly higher in the HB group (22.2% vs 1.9%, P < 0.0001), and multivariate analysis showed that heparin‐bridging therapy was an independent risk factor for PPB (OR 9.80, 95% CI 4.23–22.3, P < 0.0001). In the HB group, the polyp size was not a risk factor for PPB (OR 0.67, 95% CI 0.19–2.26, P = 0.55); the incidence of PPB in lesions of P = 0.011). Activated partial thromboplastin time and international normalized ratio were in or under the therapeutic range in the HB group when PPB occurred.Conclusions: Heparin‐bridging therapy is associated with a high risk of PPB regardless of polyp size.


  • A randomized controlled trial comparing a prepackaged low‐residue diet with a restricted diet for colonoscopy preparation: the impact on the results of colonoscopy in adenoma detection

    by T. Matsumura, M. Arai, H. Ishigami, K. Okimoto, K. Saito, S. Minemura, D. Maruoka, T. Nakagawa, T. Katsuno, O. Yokosuka

    Aim: This study aimed to investigate the clinical utility of a prepackaged low‐residue diet (PLD) compared with a restricted diet (RD) for colonoscopic bowel preparation.Method: A prospective randomized controlled trial was carried out with patients undergoing colonoscopy. One hundred patients were randomly assigned to PLD and RD groups. In the RD group, the patients received an information sheet containing acceptable low‐residue options and instructions from the medical staff. All patients received 10 ml sodium picosulphate the day before colonoscopy and 1 l of polyethylene glycol with ascorbic acid (PEG‐A) on the day of the colonoscopy. If the bowel preparation was not adequate, an additional PEG‐A solution was given. The primary outcome was the efficacy of colonic cleansing as rated by the Boston Bowel Preparation Scale (BBPS). The additional amount of PEG‐A solution, adenoma detection rate and patient tolerance were assessed as secondary outcomes.Results: The BBPS score in the PLD group was 7.3 ± 1.7 compared with 6.5 ± 1.7 in the RD group. The quality of bowel preparation was significantly better in the PLD group (P < 0.05). The mean amount of additional PEG‐A solution in the PLD group was smaller than in the RD group (293.8 ± 474.8 vs 444.1 ± 625.0 ml), but there was no statistical difference between the two groups. Adenoma detection rates and patient tolerance were similar in the two groups.Conclusion: Prepackaged low‐residue diets PLD is superior to RD for bowel preparation for colonoscopy.


  • Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: A randomized crossover study

    by Sachio Hata, Makoto Arai, Daisuke Maruoka, Takeshi Tanaka, Tomoaki Matsumura, Takuto Suzuki, Tomoo Nakagawa, Tatsuro Katsuno, Fumio Imazeki, Osamu Yokosuka